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AbstrAct
Objective
To investigate the association of plasma vitamin C 
and carotenoids, as indicators of fruit and vegetable 
intake, with the risk of type 2 diabetes.
Design
Prospective case-cohort study.
setting
Populations from eight European countries.
ParticiPants
9754 participants with incident type 2 diabetes, and 
a subcohort of 13 662 individuals from the European 
Prospective Investigation into Cancer and Nutrition 
(EPIC) cohort of 340 234 participants: EPIC-InterAct 
case-cohort study.
Main OutcOMe Measure
Incident type 2 diabetes.
results
In a multivariable adjusted model, higher plasma 
vitamin C was associated with a lower risk of 
developing type 2 diabetes (hazard ratio per standard 
deviation 0.82, 95% confidence interval 0.76 to 
0.89). A similar inverse association was shown for 
total carotenoids (hazard ratio per standard deviation 
0.75, 0.68 to 0.82). A composite biomarker score 
(split into five equal groups), comprising vitamin C 
and individual carotenoids, was inversely associated 
with type 2 diabetes with hazard ratios 0.77, 0.66, 
0.59, and 0.50 for groups 2-5 compared with group 
1 (the lowest group). Self-reported median fruit and 
vegetable intake was 274 g/day, 396 g/day, and 
508 g/day for participants in categories defined by 
groups 1, 3, and 5 of the composite biomarker score, 
respectively. One standard deviation difference in 
the composite biomarker score, equivalent to a 66 
(95% confidence interval 61 to 71) g/day difference in 
total fruit and vegetable intake, was associated with 
a hazard ratio of 0.75 (0.67 to 0.83). This would be 
equivalent to an absolute risk reduction of 0.95 per 
1000 person years of follow-up if achieved across an 
entire population with the characteristics of the eight 
European countries included in this analysis.
cOnclusiOns
These findings indicate an inverse association 
between plasma vitamin C, carotenoids, and their 
composite biomarker score, and incident type 2 
diabetes in different European countries. These 
biomarkers are objective indicators of fruit and 
vegetable consumption, and suggest that diets rich in 
even modestly higher fruit and vegetable consumption 
could help to prevent development of type 2 diabetes.
Introduction
The global burden of type 2 diabetes has risen over 
the past decades and its prevention is a public health 
priority.1 High fruit and vegetable intake has been 
suggested to have an important role in prevention 
of this disorder.2 Evidence from prospective studies 
linking fruit and vegetable intake with type 2 
diabetes is inconsistent and weak,3-5 and evidence 
from randomised controlled trials is sparse.6 Pre-
vious research studies have typically used dietary 
food frequency questionnaires to assess fruit and 
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WhAt Is AlreAdy knoWn on thIs topIc
Investigation of a link between fruit and vegetable intake and the risk of type 2 
diabetes has relied on self-reported dietary questionnaires, with inconsistent 
findings
Evidence from objective markers of fruit and vegetable intake is sparse but would 
be complementary to self-report
WhAt thIs study Adds
Results from the assessment of individual blood biomarkers and a composite 
biomarker score comprising plasma vitamin C and carotenoids indicate 
an inverse association with new onset type 2 diabetes in a pan-European 
population
This study suggests that even a modest increase in fruit and vegetable intake 
could help to prevent type 2 diabetes, indicated by objective biomarkers of 
consumption, regardless of whether the increase is among people with initially 
low or high intake
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vegetable intake, which are subject to measurement 
error and recall bias.7 Circulating plasma vitamin 
C and carotenoids have been proposed as objective 
biomarkers of fruit and vegetable intake, with evidence 
for their validity from observational and experimental 
studies.8-12 In meta-analyses of randomised controlled 
trials, groups provided with more fruits and vegetables 
had increased blood concentrations of a panel of 
fruit and vegetable related biomarkers.10-12 A meta-
analysis of up to 96 intervention studies found that 
blood vitamin C and several carotenoids were the 
most consistently responsive biomarkers for fruit and 
vegetable intake.11 In individual participant meta-
analysis of controlled intervention studies, evidence 
was found of a positive dose-response association 
between fruit and vegetable consumption and 
biomarker concentrations.12 Moreover, in comparative 
analyses, compliance at group level with fruit and 
vegetable interventions was indicated equally well 
by blood vitamin C or individual carotenoids.10 
Thus, investigation of the association between these 
biomarkers and type 2 diabetes could provide insight 
into the association of fruit and vegetable intake with 
this disorder.
Results from previous small studies describing the 
association between circulating plasma carotenoids 
and the incidence of type 2 diabetes are inconclusive, 
with an inverse association being reported in some 
studies9 13-15 and others finding no significant 
association.16 Only one previously published pros-
pective cohort study has examined circulating vitamin 
C and incident type 2 diabetes17 reporting an inverse 
association between the concentration of plasma 
vitamin C and incident type 2 diabetes in a population 
in the United Kingdom, but evidence is lacking in other 
countries or populations with different lifestyles and 
dietary behaviours.
Our study aimed at examining the association of 
baseline levels of circulating vitamin C and caro-
tenoids with incident type 2 diabetes in the European 
Prospective Investigation into Cancer and Nutrition 
(EPIC)-InterAct study, which is based on more than 
340 000 community based adults from eight European 
countries. We also aimed to construct a composite 
biomarker score to examine the association of the 
combination of biomarkers with incident type 2 
diabetes.
Methods
study design and population
The EPIC-InterAct study is a prospective case-cohort 
study, nested within the European EPIC study.18 In 
brief, cases of incident type 2 diabetes occurring in 
eight of the 10 EPIC countries (Denmark, France, 
Germany, Italy, Netherlands, Spain, Sweden, and UK) 
between 1991 and 2007 were ascertained and verified 
by the InterAct consortium across 26 study centres. 
We ascertained and verified 12 403 individuals with 
incident type 2 diabetes over 3.99 million person years 
of follow-up from a cohort of 340 234 participants with 
stored blood and buffy coat. From this cohort, a centre 
stratified subcohort was assembled by randomly 
selecting 16 835 individuals. A total of 16 154 
participants remained in the subcohort after exclusion 
of 548 with prevalent diabetes, 129 with uncertain 
diabetes status, and 4 with diabetes after censoring. 
The case-cohort design has the advantages of temporal 
sequence and power of a cohort study (in that it 
involves the complete number of incident cases) with 
the measurement efficiency of a case-control study. 
The random subcohort included 778 participants with 
verified incident type 2 diabetes, which is a design 
feature of the case-cohort approach.18 We further 
excluded 6543 participants with no plasma samples 
available for the measurement of plasma vitamin C 
(including all Swedish samples (n=5401)) and 4952 
with no carotenoids (including one Swedish centre, 
Malmo (n=3556)). We subsequently excluded those 
with samples of low volume or samples that failed 
in biochemical analysis or were haemolysed (n=218 
for vitamin C; n=85 for carotenoids). We, therefore, 
included a total of 22 833 participants, with 9754 
participants with incident type 2 diabetes and 13 662 
subcohort participants, with an average follow-up of 
9.7 years (supplemental figure S1). As a design feature 
of the case-cohort study the final eligible subcohort 
included 583 participants with incident type 2 
diabetes. For the analysis of different biomarkers, the 
sample size varied according to the number of missing 
data for the biomarkers or covariates, and the final 
sample size for each biomarker analysis is presented.
All participants gave written informed consent and 
the study was approved by the local ethics committee 
in the participating centres, and the internal review 
board of the International Agency for Research on 
Cancer.
ascertainment and verification of cases of type 2 
diabetes
Ascertainment of cases of incident type 2 diabetes 
up until 31 December 2007 involved a review of self-
reported data, linkage to primary and secondary 
care registers, use of medication (drug registers), 
hospital admissions, and mortality data, which we 
have described in detail previously.18 No cases were 
ascertained solely by self-report because we confirmed 
any self-reported case with at least one other 
independent source of information. Cases of type 2 
diabetes in Denmark and Sweden were not ascertained 
by self-report but were identified through local and 
national diabetes and pharmaceutical registers, and 
were considered verified.
Measurement of plasma vitamin c and carotenoids
Non-fasting blood samples were collected at the 
baseline visit of the EPIC study. Plasma samples stored 
at −196°C (or at −150°C for samples from Denmark) 
were shipped to Vitas Analytical Services (Oslo, 
Norway) for the measurement of plasma vitamin C 
and six individual carotenoids (α carotene, β carotene, 
lycopene, lutein, zeaxanthin, β cryptoxanthin) by 
high performance liquid chromatography-ultraviolet 
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methods, as described previously, by staff masked 
to participant information.19 20 Assays for plasma 
vitamin C and carotenoids were performed on 
separate plasma aliquots, with treatment methods 
and chromatographic procedures.19 20 For the vitamin 
C assay, meta-phosphoric acid was added to stabilise 
the vitamin C and prevent oxidation. For carotenoids, 
internal standard β apo-8-carotenal and butylated 
hydroxytoluene (as an antioxidant) were added before 
treatment. Coefficients of variation were 4.2-4.5% for 
vitamin C and 2.7-6.7% for carotenoids. The lower 
limit of detection was 0.7 µmol/L for vitamin C, 0.009 
µmol/L for α carotene and β carotene, 0.018 µmol/L 
for lycopene, 0.009 µmol/L for lutein and zeaxanthin, 
and 0.007 µmol/L for β cryptoxanthin. We imputed 
random values between zero and the lower limit of 
detection for those below the lower limit (1.0% for 
vitamin C, 1.7% for α carotene, 6.7% for zeaxanthin, 
and <0.5% for others).
To assess the reproducibility of the assay of vitamin C 
and carotenoids after long term storage, we compared 
these biomarkers in the period of measurement for this 
study (2013-14) with those previously measured in 
20049 17 in a subset of Norfolk (UK) participants of the 
EPIC study (n=1582 for vitamin C; n between 520 and 
678 for individual carotenoids). The reproducibility 
for the measurement of these biomarkers was high 
for most biomarkers (r=0.89-0.93), and moderate for 
zeaxanthin (r=0.63).
Measurement of other baseline characteristics
Baseline weight, height, and waist circumference 
were collected by trained health professionals during 
a visit to a study centre, except in France and in the 
Oxford cohort.21 Baseline dietary information was 
collected using a dietary questionnaire that was self-
administered or administered by an interviewer, which 
was developed within each country to estimate the 
usual food intake of participants.21-23 Information on 
baseline physical activity, smoking status, sociodemo-
graphic factors, and medical history was obtained 
from self-administered questionnaires.21
Serum lipid biomarkers (except for Umeå centre 
in Sweden, where plasma was used), including total 
cholesterol, high density lipoprotein cholesterol, 
and triglycerides were measured at SHL (Stichting 
Ingenhousz Laboratory, Etten-Leur, Netherlands). 
Low density lipoprotein cholesterol was calculated 
based on the Friedewald formula.24 Both high and 
low density lipoprotein cholesterol were considered 
as confounders because both can influence carotenoid 
levels (as fat soluble vitamins) and could influence 
the association between nutritional biomarker and 
disease.9 25
statistical analysis
All the statistical analyses were performed in Stata 14 
(Statacorp, College Station, TX). The concentration of 
total carotenoids was calculated as the sum of the six 
individual carotenoids. Plasma vitamin C, total, and 
six individual carotenoids (α carotene, β carotene, 
lycopene, lutein, zeaxanthin, β cryptoxanthin) were 
the exposures for this analysis. A composite biomarker 
score was generated by calculating the average of the 
standardised values (each value was standardised 
using the mean and standard deviation from the 
subcohort) of vitamin C and six individual carotenoids, 
as previously described.9 The Spearman correlations 
between plasma vitamin C and six individual 
carotenoids were calculated in the subcohort. In cross 
sectional analyses, to identify potential correlates of 
plasma vitamin C and carotenoids, we log transformed 
the values of the total and individual carotenoids, 
owing to their skewed distributions. In the subcohort, 
we used linear regression to estimate country-specific β 
coefficients and 95% confidence intervals, representing 
the associations of demographic, lifestyle, and dietary 
factors with plasma vitamin C, total and six individual 
carotenoids, and the composite biomarker score, with 
mutual adjustment for all the demographic, lifestyle, 
and dietary factors in the model. We then pooled the 
estimated associations across countries using random 
effects meta-analysis.
To help interpret the results of the composite 
biomarker score in relation to fruit and vegetable 
intake, we calculated the difference in total fruit and 
vegetable intake for each one standard deviation higher 
composite biomarker score in the subcohort using 
linear regression. These analyses included adjustment 
for age, sex, centre, physical activity, smoking status, 
employment, marital status, education, alcohol 
intake, total energy intake, body mass index, waist 
circumference, and dietary covariates (intake of 
potatoes, cereal and cereal products, milk and dairy 
products, fruit and vegetable juice, soft drinks, 
fish, red meat, legumes, egg and egg products, nuts 
and seeds, offal, and vitamin supplement use). In 
addition, we used a regression model with restricted 
cubic splines (three knots) to assess the shape of the 
association of the composite biomarker score with fruit 
and vegetable intake in the subcohort, adjusted for the 
same covariates as above.
We used Prentice weighted Cox regression26 to 
estimate country-specific hazard ratio and 95% 
confidence interval for incident type 2 diabetes, 
comparing biomarkers divided into five equal groups 
(from the lowest, group 1 to the highest, group 5) 
and for each one standard deviation (groups 1-5 
and the standard deviation were both calculated in 
the subcohort). We then pooled the estimates using 
random effects meta-analysis. We fitted three statistical 
models, adjusting for potential sociodemographic, 
lifestyle behavioural, biochemical, and anthropometric 
confounders: model 1a adjusted for age (as underlying 
time scale, continuous), sex, and centre; model 1b, as 
model 1a, plus physical activity (inactive, moderately 
inactive, moderately active, active), smoking status 
(never, former, current), employment (no, yes), marital 
status (single, married, separated/divorced, widowed), 
education (low, middle, high), alcohol drinking (never, 
0 to <6, 6 to <12, 12 to <24, and ≥24 g/day), total 
energy intake (continuous), high density lipoprotein 
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cholesterol (continuous; only for carotenoids analyses) 
and low density lipoprotein cholesterol (continuous; 
only for carotenoids analyses); and model 2, as model 
1b, plus body mass index (continuous) and waist 
circumference (continuous). Based on model 2, we 
further modelled restricted cubic spline terms (three 
knots) for analysis of each biomarker to assess the shape 
of their associations with incident type 2 diabetes.27 28 
To investigate the association with type 2 diabetes of an 
estimated daily fruit and vegetable intake that meets or 
exceeds the “five a day” recommendation (≥400 g/day) 
compared with not meeting the recommendation 
(<400 g/day), we categorised participants into two 
groups: biomarker predicted five or more portions a 
day and fewer than five portions a day, using the value 
of the composite biomarker score, which equated to 
400 grams a day of fruit and vegetable intake in the 
prediction model, as the cut-off point.
In sensitivity analyses, we imputed missing values 
of covariates using multiple imputation with chained 
equations, 29 to assess the effect of missing data on 
the biomarker-disease associations; we performed 
analysis in each of 10 imputed datasets and combined 
the estimates using Rubin’s rules. The imputation 
model included all covariates from the analysis model, 
the event variable, and the Nelson-Aalen estimate of 
cumulative hazard.29 To examine the influence of each 
individual biomarker on the composite biomarker 
score results, we amended the composite biomarker 
score by excluding one biomarker at a time, and then 
examined its association with type 2 diabetes. We also 
assessed robustness of the results from model 2 to 
take account of other potential confounders, including 
mutual adjustment for the other individual nutritional 
biomarkers (vitamin C and six individual carotenoids), 
use of vitamin supplements, season of blood draw, 
family history of diabetes, baseline prevalence of 
stroke, coronary heart diseases or cancers (excluding 
non-melanoma skin cancer), hormone use and meno-
pausal status in women, genetic risk score for body 
mass index and for insulin resistance, and a diet 
quality score (Mediterranean diet score). The genetic 
risk scores for body mass index and insulin resistance 
were both unweighted, and were calculated as the sum 
of the number of risk alleles for body mass index (97 
genetic variants)30 or insulin resistance (53 genetic 
variants).31 We also accounted for potential reverse 
causality by excluding people with haemoglobin 
A1c greater than or equal to 6.5% (48 mmol/mol) at 
baseline or those confirmed as having type 2 diabetes 
within the first two years or first four years after 
baseline. We performed further sensitivity analysis 
by excluding participants with baseline cancer or 
cardiovascular disease or by restricting the analysis 
to the first eight years of follow-up. We tested for 
multiplicative interaction between each nutritional 
biomarker and the following prespecified variables: 
age, sex, body mass index, physical activity, smoking 
status, season of blood draw, and vitamin supplement 
use. We used a lower threshold for significance 
based on the Bonferroni correction. Analyses within 
subgroups defined by the variables were performed if 
the P value for interaction was <0.05.
Patient and public involvement
No patients were involved in setting the research 
question, nor were they involved in the design and 
implementation of the study. No plans exist to involve 
patients in dissemination of the results.
results
Population characteristics
Baseline mean (standard deviation) concentration of 
plasma vitamin C and total carotenoids was 36.3 (18.3) 
and 1.3 (0.7) µmol/L, respectively, among individuals 
who developed type 2 diabetes compared with 42.3 
(19.2) µmol/L and 1.7 (0.8) µmol/L in subcohort 
participants (table 1). In the whole subcohort, partici-
pants in Germany had the highest mean levels of 
plasma vitamin C (48.4 (standard deviation 19.2) 
µmol/L), whereas those from Italy had the lowest levels 
(36.6 (18.6) µmol/L). Participants from France had the 
highest mean plasma total carotenoid levels (2.3 (1.0) 
µmol/L), whereas those from Denmark had the lowest 
levels (1.3 (0.8) µmol/L; table 1). Plasma vitamin C, 
total and individual carotenoids were all positively 
correlated with each other (supplemental table S1).
association of plasma vitamin c, total and 
individual carotenoids with potential correlates
After adjustment for demographic, lifestyle, and 
dietary factors, positive associations were found for 
sex (women compared with men), physical activity, 
and education level with both plasma vitamin C and 
total carotenoids, while waist circumference and 
current smoking status (compared with never smoking) 
were inversely associated (supplemental figure S2, 
supplemental table S2).
Dietary intake of total fruits and vegetables, citrus 
fruits, non-citrus fruits, fruiting vegetables, and fruit 
and vegetable juice were all positively associated 
with both plasma vitamin C, total carotenoids, and 
the composite biomarker score (fig 1). Each 100 g/day 
higher intake of fruits and vegetables was associated 
with 0.10 higher level of the composite biomarker 
score (fig 1); conversely, every one standard deviation 
higher composite biomarker score was associated with 
a 66 (95% confidence interval 61 to 71) g/day higher 
intake of fruits and vegetables. The median fruit and 
vegetable intake was 274, 357, 396, 452, and 508 g/day 
for levels 1 (lowest) to 5 (highest) of the composite 
biomarker score, respectively (table 2). Forest plots 
showing the association of fruit and vegetable intake 
subgroups with each plasma biomarker by country 
and overall are presented in supplemental figure S3; 
the directions of these associations were generally 
consistent across countries.
association of plasma vitamin c, total and 
individual carotenoids with incident type 2 diabetes
Higher levels of plasma vitamin C were associated 
with a lower hazard of type 2 diabetes; hazard ratio 
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subgroup
vitamin c (µmol/l)
total carotenoids 
(µmol/l)
α carotene 
(µmol/l;  
median  
(iQr))
β carotene 
(µmol/l;  
median 
(iQr))
lycopene 
(µmol/l;  
median  
(iQr))
lutein 
(µmol/l; 
median 
(iQr))
Zeaxanthin 
(µmol/l;  
median 
(iQr))
β  
cryptoxanthin 
(µmol/l;  
median (iQr))
composite 
biomarker  
score (median 
(iQr))no
Mean 
(sD) no
Median 
(iQr)
Case status:
 Non-cases 12 034 42.6 
(19.2)
13 039 1.54  
(1.11-2.08)
0.07  
(0.04-0.14)
0.38  
(0.24-0.59)
0.42  
(0.26-0.61)
0.26  
(0.19-0.36)
0.04  
(0.02-0.07)
0.20  
(0.11-0.37)
−0.04  
(−0.37-0.33)
  Cases of type  
2 diabetes 
8984 36.3 
(18.3)
9703 1.19  
(0.84-1.68)
0.05  
(0.03-0.09)
0.26  
(0.16-0.41)
0.34  
(0.20-0.53)
0.22  
(0.15-0.31)
0.03  
(0.02-0.06)
0.15  
(0.08-0.29)
−0.30  
(−0.60-0.05)
Total  
subcohort*
12 589 42.3 
(19.2)
13 618 1.52  
(1.09-2.07)
0.07  
(0.04-0.13)
0.37  
(0.23-0.58)
0.41  
(0.25-0.61)
0.26  
(0.18-0.36)
0.04  
(0.02-0.07)
0.20  
(0.11-0.37)
−0.05  
(−0.38-0.32)
Country:
 France 512 45.0 
(17.1)
536 2.22  
(1.63-2.83)
0.18  
(0.12-0.29)
0.78  
(0.52-1.08)
0.42  
(0.27-0.59)
0.36  
(0.27-0.49)
0.04  
(0.03-0.06)
0.26  
(0.17-0.41)
0.37  
(−0.02-0.75)
 Italy 1922 36.6 
(18.6)
1953 2.14  
(1.71-2.69)
0.08  
(0.05-0.14)
0.47  
(0.32-0.68)
0.65  
(0.49-0.86)
0.44  
(0.34-0.57)
0.04  
(0.03-0.05)
0.30  
(0.16-0.52)
0.24  
(−0.08-0.63)
 Spain 3499 40.8 
(16.6)
3491 1.46  
(1.09-1.93)
0.05 
(0.03-0.08)
0.27  
(0.18-0.40)
0.36  
(0.22-0.53)
0.26  
(0.19-0.34)
0.08  
(0.05-0.10)
0.33  
(0.20-0.55)
0  
(−0.30-0.33)
 UK 1257 43.4 
(20.1)
1255 1.51  
(1.14-2.01)
0.11  
(0.06-0.17)
0.46  
(0.30-0.65)
0.47  
(0.29-0.66)
0.22  
(0.17-0.30)
0.03  
(0.02-0.04)
0.15  
(0.09-0.24)
−0.13  
(−0.42-0.20)
 Netherlands 1402 48.0 
(20.9)
1438 1.35  
(1.01-1.78)
0.06  
(0.04-0.10)
0.37  
(0.24-0.52)
0.36  
(0.22-0.57)
0.23  
(0.16-0.30)
0.03  
(0.02-0.05)
0.20  
(0.12-0.33)
−0.17  
(−0.46-0.14)
 Germany 1974 48.4 
(19.2)
1990 1.56  
(1.13-2.06)
0.09  
(0.05-0.16)
0.46  
(0.29-0.74)
0.41  
(0.26-0.58)
0.24  
(0.18-0.32)
0.04  
(0.03-0.06)
0.17  
(0.10-0.28)
−0.03  
(−0.35-0.32)
 Sweden NA NA 929 1.41  
(1.06-1.86)
0.09  
(0.05-0.16)
0.42  
(0.28-0.62)
0.39  
(0.25-0.56)
0.23  
(0.17-0.30)
0.03  
(0.02-0.04)
0.13  
(0.07-0.22)
NA
 Denmark 2023 39.2 
(20.2)
2026 1.12  
(0.77-1.55)
0.08  
(0.04-0.14)
0.30  
(0.18-0.50)
0.32  
(0.20-0.48)
0.20  
(0.14-0.27)
0.02  
(0.01-0.03)
0.08  
(0.04-0.15)
−0.39  
(−0.68−0.08)
Age:
 <40 1219 43.6 
(18.7)
1486 1.56 (1.18-
2.05)
0.07  
(0.04-0.12)
0.36  
(0.23-0.56)
0.50  
(0.34-0.70)
0.24  
(0.18-0.32)
0.04  
(0.03-0.07)
0.20  
(0.12-0.34)
−0.01  
(−0.31-0.33)
 40-<60 8913 42.1 
(18.7)
9509 1.54 (1.11-
2.09)
0.07  
(0.04-0.13)
0.37  
(0.23-0.58)
0.42  
(0.26-0.62)
0.26  
(0.19-0.36)
0.04  
(0.02-0.07)
0.21  
(0.11-0.38)
−0.03  
(−0.36-0.34)
 ≥60 2457 42.5 
(21.2)
2623 1.41 (0.97-
1.95)
0.08  
(0.04-0.14)
0.40  
(0.24-0.60)
0.32  
(0.19-0.51)
0.25  
(0.18-0.35)
0.03  
(0.02-0.05)
0.17  
(0.09-0.33)
−0.15  
(−0.49-0.26)
Body mass index:
  <25 5304 45.6 
(19.9)
5891 1.68  
(1.22-2.26)
0.09  
(0.05-0.17)
0.45  
(0.29-0.71)
0.44  
(0.28-0.64)
0.27  
(0.20-0.38)
0.04  
(0.02-0.06)
0.20  
(0.11-0.36)
0.05  
(−0.28-0.45)
 25-<30 5070 40.6 
(18.5)
5412 1.46  
(1.05-1.96)
0.07  
(0.04-0.12)
0.34  
(0.21-0.52)
0.40  
(0.24-0.59)
0.25  
(0.18-0.35)
0.04  
(0.02-0.07)
0.20  
(0.11-0.37)
−0.09  
(−0.41-0.26)
 ≥30 2117 38.5 
(18.0)
2209 1.31  
(0.92-1.81)
0.05  
(0.03-0.08)
0.27  
(0.18-0.43)
0.36  
(0.21-0.55)
0.23  
(0.17-0.31)
0.04  
(0.03-0.07)
0.20  
(0.10-0.38)
−0.19  
(−0.50-0.16)
Sex:
 Male 4613 36.7 
(17.6)
5088 1.30  
(0.93-1.77)
0.06  
(0.03-0.10)
0.28  
(0.18-0.44)
0.40  
(0.24-0.61)
0.24  
(0.17-0.33)
0.04  
(0.02-0.07)
0.14  
(0.07-0.27)
−0.21  
(−0.53-0.13)
 Female 7976 45.6 
(19.4)
8530 1.67  
(1.22-2.24)
0.08  
(0.05-0.15)
0.44  
(0.28-0.67)
0.42  
(0.26-0.61)
0.27  
(0.19-0.37)
0.04  
(0.02-0.07)
0.24  
(0.13-0.42)
0.04  
(−0.28-0.43)
Education†:
 Low 5174 40.3 
(18.7)
5470 1.48  
(1.05-2.02)
0.06  
(0.03-0.10)
0.33  
(0.20-0.51)
0.38  
(0.22-0.59)
0.26  
(0.18-0.37)
0.05  
(0.03-0.08)
0.24  
(0.12-0.43)
−0.05  
(−0.39-0.33)
 Middle 4617 42.9 
(19.1)
5139 1.49  
(1.08-2.05)
0.08  
(0.04-0.14)
0.39  
(0.24-0.61)
0.42  
(0.26-0.62)
0.25  
(0.18-0.35)
0.03  
(0.02-0.06)
0.18 
(0.10-0.31)
−0.08  
(−0.40-0.29)
 High 2517 45.4 
(19.9)
2724 1.63  
(1.19-2.16)
0.09  
(0.05-0.17)
0.44  
(0.27-0.69)
0.44  
(0.29-0.62)
0.26  
(0.19-0.35)
0.04  
(0.02-0.06)
0.19  
(0.11-0.34)
0  
(−0.31-0.38)
Smoking status:
 Never 5866 45.1 
(18.3)
6431 1.66  
(1.23-2.24)
0.08  
(0.05-0.15)
0.43  
(0.28-0.65)
0.42  
(0.26-0.61)
0.27  
(0.20-0.37)
0.04  
(0.03-0.07)
0.25  
(0.14-0.44)
0.06 
(−0.26-0.43)
 Former 3359 42.6 
(18.9)
3566 1.51  
(1.08-2.04)
0.08  
(0.04-0.14)
0.37  
(0.23-0.57)
0.42  
(0.27-0.62)
0.26  
(0.19-0.36)
0.04  
(0.02-0.06)
0.19  
(0.10-0.32)
−0.07  
(−0.39-0.30)
 Current 3212 37.0 
(20.1)
3448 1.27  
(0.92-1.78)
0.05  
(0.03-0.09)
0.28  
(0.18-0.45)
0.39  
(0.23-0.59)
0.23  
(0.16-0.32)
0.04  
(0.02-0.06)
0.15  
(0.07-0.28)
−0.23  
(−0.55-0.12)
Physical activity:
 Inactive 2953 39.1 
(19.4)
3229 1.51  
(1.10-2.07)
0.06  
(0.04-0.11)
0.35  
(0.22-0.54)
0.41  
(0.24-0.61)
0.26  
(0.19-0.36)
0.04  
(0.03-0.07)
0.23  
(0.12-0.42)
−0.06  
(−0.37-0.31)
  Moderately 
inactive
4161 42.9 
(18.8)
4418 1.54  
(1.10-2.08)
0.07  
(0.04-0.13)
0.37  
(0.23-0.59)
0.42  
(0.26-0.61)
0.26  
(0.19-0.35)
0.04 
(0.02-0.07)
0.21  
(0.11-0.38)
−0.04  
(−0.37-0.33)
  Moderately 
active
2732 43.3 
(19.0)
3020 1.53  
(1.10-2.08)
0.08  
(0.05-0.15)
0.39  
(0.24-0.62)
0.41  
(0.25-0.61)
0.26  
(0.18-0.36)
0.04  
(0.02-0.06)
0.19  
(0.10-0.34)
−0.04  
(−0.37-0.36)
 Active 2542 44.3 
(19.5)
2745 1.50  
(1.06-2.04)
0.08  
(0.04-0.14)
0.38  
(0.23-0.59)
0.41  
(0.25-0.60)
0.25  
(0.18-0.35)
0.03  
(0.02-0.06)
0.18  
(0.09-0.32)
−0.07  
(−0.41-0.30)
table 1 | Distribution of plasma vitamin c and carotenoids by case status and by population characteristics in the subcohort of ePic-interact study
(Continued)
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for each standard deviation 0.71 (95% confidence 
interval 0.65 to 0.78) in a model adjusted for age, sex, 
and study centre (model 1a). Hazard ratios comparing 
groups 2, 3, 4, and 5 of vitamin C with group 1 (the 
lowest group) were 0.84 (0.77 to 0.92), 0.61 (0.53 to 
0.71), 0.53 (0.46 to 0.61), and 0.39 (0.31 to 0.50). 
These inverse associations were attenuated after 
further adjustment for socioeconomic factors, lifestyle 
factors, and adiposity (model 2), but the trend across 
the groups remained: hazard ratios 0.94 (0.83 to 1.08), 
0.72 (0.60 to 0.87), 0.68 (0.56 to 0.82), and 0.58 (0.47 
to 0.72) comparing groups 2, 3, 4, and 5, with group 1, 
respectively (table 2).
For plasma total carotenoids, the inverse association 
with type 2 diabetes estimated in models 1a and 1b 
was attenuated after further adjustment for adiposity 
(model 2), but remained significant. The hazard ratio 
for each standard deviation of total carotenoids was 
0.75 (95% confidence interval 0.68 to 0.82). The 
hazard ratios comparing groups 2, 3, 4, and 5 of total 
carotenoids with group 1 were 0.83 (0.74 to 0.92), 
0.64 (0.54 to 0.75), 0.61 (0.53 to 0.70), and 0.51 (0.43 
to 0.60), respectively. In model 2, all plasma individual 
carotenoids were inversely associated with type 2 
diabetes, except for zeaxanthin (table 2). For plasma 
total and individual carotenoids, the heterogeneity 
(I2) across countries ranged from 48.0% for β 
cryptoxanthin to 75.2% for β carotene (supplemental 
figure S4), but the directions of the associations were 
consistent across different countries.
The composite biomarker score, which included 
contributions from all the examined biomarkers, 
was inversely associated with type 2 diabetes. The 
hazard ratios comparing groups 2, 3, 4, and 5 of the 
combined biomarker score with group 1 were 0.77 
(0.68 to 0.87), 0.66 (0.54 to 0.80), 0.59 (0.48 to 0.72), 
and 0.50 (0.40 to 0.62), respectively. One standard 
deviation difference in the composite biomarker score, 
equivalent to a 66 (95% confidence interval 61 to 71) 
g/day difference in total fruit and vegetable intake, was 
associated with a hazard ratio of 0.75 (95% confidence 
interval 0.67 to 0.83). This would be equivalent to an 
absolute risk reduction of 0.95 per 1000 person years 
of follow-up if achieved across an entire population 
table 1 | continued
subgroup
vitamin c (µmol/l)
total carotenoids 
(µmol/l)
α carotene 
(µmol/l;  
median  
(iQr))
β carotene 
(µmol/l;  
median 
(iQr))
lycopene 
(µmol/l;  
median  
(iQr))
lutein 
(µmol/l; 
median 
(iQr))
Zeaxanthin 
(µmol/l;  
median 
(iQr))
β  
cryptoxanthin 
(µmol/l;  
median (iQr))
composite 
biomarker  
score (median 
(iQr))no
Mean 
(sD) no
Median 
(iQr)
Alcohol intake (g/day):
 0 2129 40.9 
(18.6)
2213 1.60  
(1.14-2.14)
0.06  
(0.04-0.11)
0.36  
(0.24-0.55)
0.39  
(0.24-0.59)
0.26  
(0.19-0.37)
0.05  
(0.03-0.08)
0.28  
(0.15-0.49)
−0.01  
(−0.32-0.36)
 0-<6 3885 44.9 
(19.2)
4639 1.60  
(1.16-2.18)
0.09  
(0.05-0.16)
0.43  
(0.28-0.65)
0.42  
(0.25-0.62)
0.25  
(0.18-0.35)
0.04  
(0.02-0.06)
0.21  
(0.11-0.38)
0.01  
(−0.32-0.41)
 6-<12 1847 43.8 
(19.3)
1969 1.56  
(1.12-2.10)
0.08  
(0.05-0.15)
0.41  
(0.26-0.63)
0.42  
(0.27-0.62)
0.25  
(0.18-0.35)
0.04  
(0.02-0.06)
0.19  
(0.10-0.33)
−0.04 
(−0.38-0.33)
 12-<24 2054 42.7 
(19.0)
2104 1.52  
(1.11-2.04)
0.07  
(0.04-0.14)
0.37  
(0.23-0.57)
0.43  
(0.27-0.62)
0.26  
(0.19-0.36)
0.04  
(0.02-0.06)
0.19  
(0.10-0.35)
−0.06  
(−0.38-0.31)
 ≥24 2624 38.4 
(19.2)
2643 1.31  
(0.93-1.80)
0.06  
(0.03-0.10)
0.27  
(0.15-0.43)
0.39  
(0.24-0.58)
0.25  
(0.18-0.36)
0.04  
(0.02-0.07)
0.16  
(0.07-0.29)
−0.17  
(−0.51-0.18)
Marital status:
 Single 614 46.7 
(20.4)
730 1.56  
(1.17-2.27)
0.09  
(0.05-0.17)
0.43  
(0.26-0.71)
0.47  
(0.28-0.66)
0.26  
(0.18-0.37)
0.04  
(0.02-0.05)
0.18  
(0.11-0.32)
0.02  
(−0.30-0.47)
 Married 5491 43.5 
(19.7)
6299 1.68  
(1.22-2.26)
0.09  
(0.05-0.15)
0.45  
(0.30-0.68)
0.47  
(0.29-0.67)
0.28  
(0.20-0.40)
0.04  
(0.02-0.05)
0.19 
(0.11-0.34)
0.02  
(−0.31-0.40)
  Separated/ 
divorced
508 47.8 
(21.4)
573 1.63  
(1.18-2.12)
0.09  
(0.05-0.16)
0.45  
(0.29-0.67)
0.44  
(0.28-0.63)
0.24  
(0.18-0.34)
0.04  
(0.02-0.06)
0.19  
(0.10-0.31)
0.02  
(−0.30-0.36)
 Widowed 284 42.9 
(21.1)
318 1.62  
(1.15-2.08)
0.09  
(0.05-0.14)
0.46  
(0.28-0.65)
0.41  
(0.25-0.58)
0.26  
(0.19-0.37)
0.03  
(0.02-0.05)
0.21  
(0.12-0.36)
−0.02  
(−0.37-0.28)
Employment:
 No 3054 42.3 
(21.0)
3313 1.55  
(1.07-2.17)
0.08  
(0.05-0.14)
0.43  
(0.27-0.66)
0.40  
(0.24-0.61)
0.27  
(0.18-0.39)
0.03  
(0.02-0.05)
0.19  
(0.10-0.33)
−0.06  
(−0.42-0.34)
 Yes 5879 43.2 
(19.7)
6657 1.54  
(1.11-2.10)
0.09  
(0.05-0.16)
0.42  
(0.26-0.64)
0.44  
(0.28-0.64)
0.25  
(0.18-0.35)
0.03  
(0.02-0.05)
0.16  
(0.09-0.29)
−0.08  
(−0.41-0.31)
HDL-C:‡
  Low (<1.4 
mmol/L)
4862 38.5 
(18.1)
5395 1.34  
(0.96-1.84)
0.06  
(0.04-0.11)
0.31  
(0.19-0.49)
0.39  
(0.24-0.59)
0.23  
(0.16-0.32)
0.04  
(0.02-0.06)
0.17  
(0.09-0.31)
−0.19  
(−0.50-0.15)
  High (≥1.4 
mmol/L)
7468 44.9 
(19.5)
7959 1.65  
(1.20-2.22)
0.08  
(0.05-0.15)
0.42  
(0.27-0.64)
0.43  
(0.27-0.62)
0.28  
(0.20-0.38)
0.04  
(0.02-0.07)
0.23  
(0.12-0.41)
0.04  
(−0.29-0.43)
LDL-C:‡
  Low  
(<3.7 mmol/L)
6016 43.4 
(19.0)
6545 1.44  
(1.04-1.94)
0.07  
(0.04-0.13)
0.35  
(0.22-0.55)
0.39  
(0.24-0.57)
0.24  
(0.17-0.33)
0.04  
(0.02-0.06)
0.19  
(0.10-0.34)
−0.11  
(−0.41-0.24)
  High (≥3.7 
mmol/L)
6169 41.6 
(19.4)
6662 1.62  
(1.16-2.20)
0.07  
(0.04-0.13)
0.40  
(0.25-0.61)
0.44  
(0.27-0.65)
0.27  
(0.20-0.38)
0.04  
(0.02-0.07)
0.22  
(0.11-0.40)
0.01  
(−0.33-0.40)
HDL-C=high density lipoprotein cholesterol; IQR=interquartile range; LDL-C=low density lipoprotein cholesterol; NA=not available; SD=standard deviation.
Vitamin C was not measured in the Swedish cohort owing to sample availability.
*Distribution of the biomarkers by population characteristics was from the subcohort of EPIC-InterAct Study, except for the first two rows describing distribution among future cases and non-cases. 
†Education: low=none or primary school completed; middle=technical/professional or secondary school; high=longer education (including university degree).
‡Cut-off values for low or high levels of high density lipoprotein cholesterol and low density lipoprotein cholesterol are based on the population median in the subcohort.
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with the characteristics of the eight European countries 
included in this analysis. Thus the crude overall 
incidence rate of type 2 diabetes would be estimated to 
be reduced from 3.8 to 2.85 per 1000 person years of 
follow-up in this population. 
We found evidence of non-linear associations 
(P value for non-linearity <0.001) for plasma total 
carotenoids, α carotene, β carotene, and lutein, with 
a strong inverse association with type 2 diabetes at 
low to moderate concentrations, but weaker at higher 
concentrations (fig 2). The shape of the associations 
of the composite biomarker score with total fruit and 
vegetable intake and with type 2 diabetes is presented 
in figure 3. In an analysis of the association with type 
2 diabetes using this biomarker score as a cut-off level 
to define consumption of five or more portions a day of 
fruits and vegetables, the hazard ratio compared with 
consuming an estimated fewer than five portions a day 
was 0.69 (95% confidence interval 0.63 to 0.76).
In a sensitivity analysis, after mutual adjustment for 
the other individual biomarkers, the inverse association 
with type 2 diabetes for each of the biomarkers was 
attenuated (supplemental table S3). Lycopene and β 
cryptoxanthin were no longer significantly associated 
with type 2 diabetes. Other sensitivity analyses had 
little effect on the findings (supplemental tables S3 
and S4).
We identified evidence of a significant interaction 
only between baseline age and both plasma vitamin 
C and α carotene (P value for interaction <0.001), 
with the inverse associations with type 2 diabetes 
being weaker in the oldest age group (supplemental 
figure S5).
discussion
In this large study with dietary diversity across eight 
European countries, higher concentrations of plasma 
vitamin C and carotenoids were associated with 
Total fruits and vegetables (per 100 g/day)
Citrus fruits (per 100 g/day)
Non-citrus fruits (per 100 g/day)
Green leafy vegetables (per 100 g/day)
Fruiting vegetables (per 100 g/day)
Root vegetables (per 100 g/day)
Cabbage (per 100 g/day)
Other vegetables (per 100 g/day)
Potatoes (per 100 g/day)
Cereal and cereal products (per 200 g/day)
Milk and dairy products (per 200 g/day)
Fruit and vegetable juice (per 200 g/day)
So drinks (per 200 g/day)
Fish (per 100 g/day)
Red meat (per 100 g/day)
Legumes (per 50 g/day)
Egg and egg products (per 50 g/day)
Nuts and seeds (per 10 g/day)
Offals (per 10 g/day)
Vitamin supplement use (ref: no), yes
431 (260)
60 (75)
182 (146)
31 (44)
66 (55)
20 (27)
19 (28)
53 (54)
95 (75)
222 (115)
292 (235)
61 (112)
66 (151)
37 (34)
47 (36)
20 (29)
19 (17)
3 (8)
2 (5)
39.4
Mean
(SD)/%
Total
carotenoids
Vitamin C β
carotene
α
carotene
LuteinLycopene β
cryptox-
anthin
Zeaxanthin Composite
biomarker
score
0.08
0.19
0.05
0.04
0.12
0.10
0.12
0.01
0.03
0.03
-0.01
0.28
0
0.15
-0.09
0
-0.08
0.02
0.03
0.27
0.09
0.18
0.03
0.01
0.21
0.39
0.10
0.05
0.02
0.19
0.01
0.14
-0.02
0.13
0.05
0.03
-0.02
0.05
-0.01
0.05
0.10
0.02
0.06
-0.07
0.05
1.20
0.20
-0.01
0.02
0.16
0.03
0.08
-0.05
0.07
-0.02
0.02
-0.07
0.03
0
0.06
0.07
0.05
0.04
0.09
0.14
0.50
0.15
0.03
0
0.11
0.03
0.09
-0.02
0.07
-0.01
0
-0.05
0.02
0
0.09
-0.12 0 1.20
0.03
0.05
-0.01
-0.12
0.38
-0.07
-0.03
0.08
0.03
0.25
0.01
0.04
0
0.09
0.16
0.04
-0.05
0.06
0
-0.05
0.06
0.02
0.02
0.34
0.11
0.10
0.25
0.14
0.03
0.15
-0.02
0.08
-0.04
0.09
-0.06
0
0.11
0.03
-0.03
-0.04
0.02
0.16
-0.03
0.08
0.07
-0.09
0
0.03
-0.01
-0.04
-0.02
0.28
-0.02
0.05
-0.01
-0.07
0.16
0.03
-0.01
0.02
0.10
0.51
0.04
-0.03
0.10
-0.01
0.01
0.03
-0.01
0.01
0
0.24
-0.02
0
0.01
-0.06
-0.06
0.03
0
0.01
0.10
0.22
0.03
0.09
0.23
0.44
0.09
0.05
0.02
0.16
0.01
0.25
-0.02
0.15
-0.02
0.02
0.02
0.04
0
0.11
‡
‡
‡
*
‡
*
*
*
*
‡
‡
*
†
‡
†
‡
*
‡
‡
‡
‡
‡
*
*
†
‡
‡
‡
*
*
‡
*
*
*
†
*
*
‡
*
‡
‡
*
*
*
‡
*
†
*
*
*
‡
†
*
*
†
*
*
*
‡
*
*
*
‡
*
‡
‡
‡
†
*
‡
‡
‡
†
†
‡
*
‡
Fig 1 | association of dietary factors with plasma vitamin c and carotenoids in the subcohort of the european Prospective investigation into cancer 
and nutrition (ePic)-interact study. the values in the box represent the differences in vitamin c, carotenoids, or the composite biomarker score (in 
standard deviaiton units) for each one standardised unit per category difference in dietary factors. the mean (standard deviation) or percentage of 
participants for the examined dietary factors are presented in the second column. linear regression was used to obtain the country specific estimate 
of an association, adjusting for demographic, lifestyle, and other examined dietary factors if available in that country, except the overlapping food 
groups. the country-specific estimates were then combined using random effects meta-analysis. *P<0.05; †P<0.001; ‡P<0.0001. sample size was 
10 584 for vitamin c and 11 537 for the carotenoid estimation. all the values are expressed in a red scale for different levels of positive associations 
and blue scale for different levels of negative associations. all the carotenoids variables were natural log transformed before statistical analysis 
in the linear regression. standard deviation was 19.2 µmol/l for vitamin c, 0.50 for total carotenoids (log transformed), 0.91 for α carotene (log 
transformed), 0.73 for β carotene (log transformed), 0.68 for lycopene (log transformed), 0.51 for lutein (log transformed), 0.91 for zeaxanthin (log 
transformed), 0.94 for β cryptoxanthin (log transformed), and 0.57 for the composite biomarker score. a β coefficient of 0.10 represents the increase 
in the composite biomarker score per 100 g/day of fruit and vegetable intake. Performing this cross sectional analysis the other way round, every 
change in one standard deviation in the composite biomarker score was associated with a 66 g/day increase in fruit and vegetable intake
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a lower incidence of type 2 diabetes. A composite 
biomarker score, comprising the seven examined 
biomarkers, was associated with consumption of fruit 
and vegetables and was also inversely related to the 
risk of type 2 diabetes. These findings provide strong 
evidence from objectively measured biomarkers for 
the recommendation that fruit and vegetable intake 
should be increased to prevent type 2 diabetes.
strengths and limitations of this study
The strengths of our study include our report of 
the association of plasma vitamin C and individual 
table 2 | Prospective associations between plasma vitamin c and carotenoids and incident type 2 diabetes in the ePic-interact study*
Hazard ratio (95% confidence interval)† P value 
for 
trendgroup 1 group 2 group 3 group 4 group 5
For each one  
standard deviation
Vitamin C, (median, µmol/L) 17.0 32.8 42.3 51.2 64.9 — —
 No of cases/person years 2431/13 089 2042/13 166 1482/13 337 1256/14 898 949/17 420 — —
 Model 1a 1.0 (ref) 0.84 (0.77 to 0.92) 0.61 (0.53 to 0.71) 0.53 (0.46 to 0.61) 0.39 (0.31 to 0.50) 0.71 (0.65 to 0.78) <0.001
 Model 1b 1.0 (ref) 0.87 (0.80 to 0.96) 0.65 (0.56 to 0.76) 0.57 (0.50 to 0.66) 0.43 (0.34 to 0.54) 0.74 (0.68 to 0.80) <0.001
 Model 2 1.0 (ref) 0.94 (0.83 to 1.08) 0.72 (0.60 to 0.87) 0.68 (0.56 to 0.82) 0.58 (0.47 to 0.72) 0.82 (0.76 to 0.89) <0.001
Total carotenoids,  
(median, µmol/L)
0.75 1.17 1.52 1.93 2.70 — —
 No of cases/person years 2952/10 116 1944/11 940 1316/14 155 1127/16 904 874/19 899 — —
 Model 1a 1.0 (ref) 0.67 (0.61 to 0.74) 0.43 (0.37 to 0.52) 0.35 (0.28 to 0.42) 0.24 (0.18 to 0.32) 0.53 (0.47 to 0.61) <0.001
 Model 1b 1.0 (ref) 0.72 (0.62 to 0.83) 0.51 (0.44 to 0.60) 0.43 (0.36 to 0.52) 0.31 (0.24 to 0.40) 0.60 (0.53 to 0.67) <0.001
 Model 2 1.0 (ref) 0.83 (0.74 to 0.92) 0.64 (0.54 to 0.75) 0.61 (0.53 to 0.70) 0.51 (0.43 to 0.60) 0.75 (0.68 to 0.82) <0.001
α carotene, (median, µmol/L) 0.02 0.05 0.07 0.12 0.23 — —
 No of cases/person years 2629/10 061 1922/13 665 1571/15 458 1254/16 266 837/17 564 — —
 Model 1a 1.0 (ref) 0.72 (0.65 to 0.80) 0.54 (0.46 to 0.62) 0.46 (0.41 to 0.52) 0.29 (0.24 to 0.35) 0.57 (0.48 to 0.68) <0.001
 Model 1b 1.0 (ref) 0.75 (0.66 to 0.86) 0.60 (0.52 to 0.69) 0.53 (0.47 to 0.60) 0.36 (0.30 to 0.43) 0.65 (0.56 to 0.76) <0.001
 Model 2 1.0 (ref) 0.81 (0.70 to 0.94) 0.72 (0.64 to 0.82) 0.69 (0.59 to 0.79) 0.53 (0.46 to 0.62) 0.79 (0.72 to 0.88) <0.001
β carotene, (median, µmol/L) 0.14 0.26 0.37 0.53 0.87 — —
 No of cases/person years 2911/8142 2064/11 861 1417/15 096 1035/17 520 786/20 395 — —
 Model 1a 1.0 (ref) 0.68 (0.60 to 0.78) 0.44 (0.40 to 0.49) 0.33 (0.28 to 0.37) 0.24 (0.20 to 0.28) 0.48 (0.40 to 0.58) <0.001
 Model 1b 1.0 (ref) 0.70 (0.61 to 0.80) 0.48 (0.43 to 0.54) 0.38 (0.34 to 0.43) 0.29 (0.26 to 0.34) 0.55 (0.46 to 0.65) <0.001
 Model 2 1.0 (ref) 0.78 (0.69 to 0.88) 0.60 (0.54 to 0.68) 0.53 (0.47 to 0.60) 0.45 (0.39 to 0.52) 0.71 (0.62 to 0.82) <0.001
Lycopene, (median, µmol/L) 0.15 0.28 0.41 0.56 0.82 — —
 No of cases/person years 2395/10 449 1879/12 779 1447/13 840 1299/16 393 1193/19 553 — —
 Model 1a 1.0 (ref) 0.79 (0.69 to 0.90) 0.66 (0.60 to 0.73) 0.57 (0.48 to 0.69) 0.50 (0.38 to 0.64) 0.76 (0.68 to 0.85) <0.001
 Model 1b 1.0 (ref) 0.89 (0.80 to 0.99) 0.73 (0.65 to 0.82) 0.68 (0.59 to 0.78) 0.59 (0.47 to 0.75) 0.81 (0.75 to 0.89) <0.001
 Model 2 1.0 (ref) 0.95 (0.86 to 1.06) 0.84 (0.75 to 0.94) 0.81 (0.71 to 0.92) 0.79 (0.68 to 0.93) 0.91 (0.85 to 0.98) 0.01
Lutein, (median, µmol/L) 0.13 0.20 0.25 0.33 0.49 — —
 No of cases/person years 2508/11 727 1856/11 950 1464/13 668 1268/14 951 1117/2 0718 — —
 Model 1a 1.0 (ref) 0.72 (0.66 to 0.79) 0.52 (0.44 to 0.61) 0.41 (0.32 to 0.51) 0.30 (0.24 to 0.38) 0.57 (0.48 to 0.68) <0.001
 Model 1b 1.0 (ref) 0.79 (0.72 to 0.87) 0.64 (0.57 to 0.71) 0.56 (0.48 to 0.65) 0.49 (0.42 to 0.56) 0.70 (0.62 to 0.79) <0.001
 Model 2 1.0 (ref) 0.89 (0.78 to 1.01) 0.75 (0.65 to 0.86) 0.70 (0.59 to 0.82) 0.65 (0.55 to 0.78) 0.84 (0.77 to 0.91) <0.001
Zeaxanthin, (median, µmol/L) 0.01 0.03 0.04 0.06 0.10 — —
 No of cases/person years 2159/13 624 1658/17 107 1510/18 591 1479/15 470 1407/8222 — —
 Model 1a 1.0 (ref) 0.87 (0.74 to 1.01) 0.77 (0.66 to 0.90) 0.70 (0.58 to 0.85) 0.55 (0.47 to 0.65) 0.76 (0.68 to 0.85) <0.001
 Model 1b 1.0 (ref) 0.92 (0.78 to 1.09) 0.89 (0.78 to 1.01) 0.84 (0.67 to 1.05) 0.71 (0.59 to 0.86) 0.87 (0.80 to 0.94) <0.001
 Model 2 1.0 (ref) 0.95 (0.84 to 1.07) 0.98 (0.86 to 1.13) 0.99 (0.78 to 1.27) 0.86 (0.66 to 1.12) 0.96 (0.88 to 1.05) 0.34
β cryptoxanthin, (median, µmol/L) 0.05 0.12 0.20 0.32 0.61 — —
 No of cases/person years 2431/10 990 1712/15 889 1494/16 483 1379/15 438 1197/14 213 — —
 Model 1a 1.0 (ref) 0.75 (0.63 to 0.89) 0.63 (0.52 to 0.77) 0.58 (0.49 to 0.69) 0.42 (0.31 to 0.56) 0.64 (0.55 to 0.75) <0.001
 Model 1b 1.0 (ref) 0.77 (0.65 to 0.91) 0.74 (0.64 to 0.87) 0.66 (0.56 to 0.78) 0.51 (0.38 to 0.69) 0.75 (0.67 to 0.84) <0.001
 Model 2 1.0 (ref) 0.81 (0.68 to 0.97) 0.81 (0.69 to 0.95) 0.83 (0.72 to 0.96) 0.72 (0.56 to 0.93) 0.88 (0.81 to 0.96) 0.001
Composite biomarker score 
(median)
−0.66 −0.31 −0.05 0.23 0.74 — —
Fruit and vegetable intake  
(median, g/day)
274 357 396 452 508 — —
 No of cases/person years 2752/10 909 1719/13 249 1249/14 624 1047/15 582 770/17 471 — —
 Model 1a 1.0 (ref) 0.61 (0.53 to 0.70) 0.43 (0.35 to 0.53) 0.32 (0.24 to 0.43) 0.22 (0.17 to 0.30) 0.55 (0.48 to 0.63) <0.001
 Model 1b 1.0 (ref) 0.67 (0.59 to 0.77) 0.52 (0.44 to 0.62) 0.42 (0.33 to 0.52) 0.31 (0.25 to 0.39) 0.61 (0.55 to 0.69) <0.001
 Model 2 1.0 (ref) 0.77 (0.68 to 0.87) 0.66 (0.54 to 0.80) 0.59 (0.48 to 0.72) 0.50 (0.40 to 0.62) 0.75 (0.67 to 0.83) <0.001
*Sample size is 19 255 for vitamin C, 19 907 for carotenoids, and 18 276 for the composite biomarker score. Numbers (N) of cases and person years (subcohort) by the biomarker split into five 
equal groups (group 1, the lowest; group 5, the highest) are presented. 
Model 1a: adjusted for age (as underlying timescale), sex and centre; model 1b: model 1a+physical activity, smoking status, employment, marital status, education, alcohol intake, total energy 
intake, high density lipoprotein cholesterol, and low density lipoprotein cholesterol; model 2: model 1b+adiposity (body mass index and waist circumference). Model 1b and model 2 of plasma 
vitamin C were not adjusted for high and low density lipoprotein cholesterol.
†Hazard ratios for groups 1-4 (compared with group 1) and for each one standard deviation (SD) of each biomarker, were estimated from country-specific, Prentice weighted Cox regression 
models; estimates were then combined across countries by random effects meta-analysis. P value for trend was calculated as the trend per group for each biomarker. The plasma composite 
biomarker score was generated by calculating the average of the z scores of vitamin C and six individual carotenoids. Standard deviation was 19.2 µmol/L for vitamin C, 0.83 µmol/L for total 
carotenoids, 0.12 µmol/L for α carotene, 0.41 µmol/L for β carotene, 0.27 µmol/L for lycopene, 0.15 µmol/L for lutein, 0.04 µmol/L for zeaxanthin, 0.29 µmol/L for β cryptoxanthin, and 0.57 for 
the composite biomarker score.
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carotenoids with type 2 diabetes in a large case-cohort 
study. The study included a subcohort of 13 662 
individuals and 9754 participants with incident 
type 2 diabetes, from an original cohort of 340 234 
participants with 3.99 million person years of follow-
up. This analysis, based on predominantly white 
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Fig 2 | associations of plasma vitamin c and carotenoids with incident type 2 diabetes in the european Prospective investigation into cancer and 
nutrition (ePic)-interact study. the purple solid line and the shaded area represent estimates of hazard ratios and the 95% confidence intervals, 
respectively, for each biomarker (median in the subcohort as a reference). covariates included age (as underlying time scale), sex, centre, physical 
activity, smoking status, employment, marital status, education, alcohol intake, total energy intake, high density lipoprotein cholesterol (for 
analyses of carotenoids only), low density lipoprotein cholesterol (for analyses of carotenoids only), body mass index, and waist circumference. For 
total carotenoids, α carotene, β carotene, and lutein, we found evidence of a non-linear association (P value for non-linearity <0.001)
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participants from eight European countries, indicates 
the generalisability of the study findings to populations 
of European descent, though further research in other 
populations is warranted. The number of participants 
with incident type 2 diabetes in this study was 10-fold 
greater than in previous studies of the association of 
biomarkers of fruit and vegetable intake with risk of 
type 2 diabetes, which not only provided high statistical 
power for the main effect analyses but also permitted a 
dose-response analysis and other sensitivity analyses.
This study has several limitations. The biomarkers 
could degrade during storage over years, which would 
make it difficult to quantify the absolute concentration 
of vitamin C and carotenoids. The likelihood of degra-
dation in this study was minimised, however, by storing 
the samples in liquid nitrogen and if it did occur, 
it should be the same in cases and non-cases. The 
vitamin C and carotenoid biomarkers were measured 
only at baseline, and intra-individual variation over 
time is likely. However, when follow-up was restricted 
to the first 8 years, the associations remained similar. 
Another limitation is the observational nature of this 
study and the potential for residual confounding 
due to mis-measured or unmeasured confounders. 
The inverse associations we observed could, in part, 
be explained by the confounding effect of a healthy 
lifestyle and favourable socioeconomic conditions, 
which might not have been fully accounted for in the 
analyses. Moreover, differential misclassification in 
ascertainment of type 2 diabetes could have occurred if 
those with high fruit and vegetable consumption were 
more health conscious, sought medical assessment, 
and hence were diagnosed with the disorder. This 
possibility could cause bias towards the null and 
an underestimation of the inverse association. The 
results could be explained by reverse causality, 
but our sensitivity analysis indicated that this was 
unlikely. An assessment of causal associations of 
these nutritional biomarkers with type 2 diabetes 
was beyond the scope of our study. In addition, a 
common limitation for nutritional biomarkers is that 
their relationship with diet is often influenced by both 
genetic variation and nutrient metabolism.32 Further 
challenges in interpretation arise. Thus the presence 
of these biomarkers might not be exclusively due to 
the consumption of fruit and vegetables, but some 
carotenoids, for instance, could also originate from the 
food production process, such as food colouring. The 
biomarkers could reflect underlying dietary patterns 
or food substitution effects when fruit or vegetables 
replace meat in the diet, for instance.
comparison with other studies
Evidence from previous studies for the magnitude 
of the association between circulating vitamin C and 
carotenoids and the risk of type 2 diabetes is limited, 
mainly because of the small number of participants in 
previous studies.13 14 16 17 Additionally, those studies 
did not investigate differences in those associations by 
country. Biomarkers can be used not only to investigate 
the relationship between total fruit and vegetables 
and the risk of diabetes but can also help to examine 
the effect of specific fruit and vegetable subgroups. 
For example, α carotene and β carotene were highly 
correlated with root vegetables, in this and a previous 
study.8 Therefore, the biomarker finding of α carotene 
and β carotene could suggest a potential inverse 
association with type 2 diabetes for root vegetables; 
this deserves further study. In this study, the inverse 
association between some biomarkers and type 2 
diabetes was attenuated when mutually adjusted for 
the other individual biomarkers. These results suggest 
that a combination of nutrients in fruit and vegetables 
explains the association with type 2 diabetes rather 
than a single nutrient. Thus our finding of an inverse 
association between the biomarker composite score 
and risk of type 2 diabetes could be capturing this 
combined effect.
Our results could also provide a possible explanation 
of the previous null findings of randomised trials 
for single vitamin supplements. In the Women’s 
Antioxidant Cardiovascular Study, dietary supple-
ments of vitamin C, vitamin E, or β carotene had no 
significant effects on the risk of developing type 2 
diabetes during a follow-up of 9.2 years.33 Similarly, 
long term β carotene supplementation did not affect 
the risk of incident type 2 diabetes among healthy men 
in a randomised trial over a 12 year follow-up period,34 
or in male smokers in a randomised trial with 6.1 years 
of follow-up.35 The absence of a significant intervention 
effect on the risk of developing type 2 diabetes in 
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Fig 3 | associations of plasma composite biomarker score with incident type 2 diabetes 
and total fruit and vegetable intake in the european Prospective investigation into 
cancer and nutrition (ePic)-interact study. the purple solid line and shaded areas 
represent hazard ratios and 95% confidence intervals for the association of the 
composite biomarker score with type 2 diabetes (median as a reference), adjusted 
for age (as underlying time scale), sex, centre, physical activity, smoking status, 
employment, marital status, education, alcohol intake, total energy intake, high density 
lipoprotein cholesterol, low density lipoprotein cholesterol, body mass index, and 
waist circumference. the red dashed lines represent the association of the composite 
biomarker score with fruit and vegetable intake (best estimates and their 95% 
confidence intervals), adjusted for age, sex, centre, physical activity, smoking status, 
employment, marital status, education, alcohol intake, total energy intake, body mass 
index, waist circumference, and dietary intake of potatoes, cereal and cereal products, 
milk and dairy products, fruit and vegetable juice, soft drinks, fish, red meat, legumes, 
egg and egg products, nuts and seeds, offals, and vitamin supplement use. P values for 
non-linearity were 0.056 for the hazard ratios, and <0.001 for estimates for fruit and 
vegetable intake. the vertical lines within the figure represent the quintiles (20th, 40th, 
60th, and 80th centiles) of the composite biomarker score in the subcohort
RESEARCH
the bmj | BMJ 2020;370:m2194 | doi: 10.1136/bmj.m2194 11
these trials could have been because they focused 
on supplementation of these individual nutrients 
themselves rather than the foods or a dietary pattern 
for which these nutrients are objective biomarkers. 
Fruits and vegetables contain many other components 
besides vitamin C and carotenoids, including fibre, 
phytochemicals such as flavonoids, and other 
antioxidants, all of which could have beneficial health 
effects.36 Alternatively, the null results for vitamin 
supplementation trials could be explained by the focus 
of those trials on individual rather than composite 
nutrients, or their focus on increasing average levels 
rather than reducing deficiency. We observed non-
linear associations for carotenoids, and thus the effect 
of supplementation on type 2 diabetes could be greater 
in those who had lower levels at baseline. Finally, the 
distribution of vitamin levels differed in those trials 
from that in our observational study. We found a mean 
concentration of plasma β carotene of 0.47 µmol/L. 
This result contrasts with a mean of 2.24 µmol/L in the 
Women’s Antioxidant Cardiovascular Study33 and 5.6 
µmol/L in the Alpha-Tocopherol, Beta-Carotene Cancer 
Prevention Study,35 after β carotene intervention of 50 
mg every other day or 20 mg each day, respectively.
The potential mechanisms of association could 
be that consumption of fruit and vegetables helps to 
regulate weight and adiposity, as well as glucose-
insulin homoeostasis and the inflammatory status 
of the participants,37 38 thus leading to a reduced 
risk of type 2 diabetes. Another possible mechanism 
is the influence of the fruit and vegetable intake on 
the gut microbiota, given their high concentration of 
fibre or other gut microbiota-related nutrients.39 40 
A sensitivity analysis of additional adjustment for a 
diet quality score did not alter the findings for any of 
the biomarkers, which further confirms that higher 
fruit and vegetable intake is likely to be beneficial for 
prevention of type 2 diabetes regardless of the overall 
diet quality. We could not rule out the possibility, 
however, that the observed association partly reflected 
metabolic effects independent of dietary factors.
What this study adds
Various dietary guidelines have recommended 
increasing fruit and vegetable intake as an important 
component of a healthy diet. However, evidence derived 
from a food frequency questionnaire for the specific 
role of fruit and vegetables and their subtypes in the 
prevention of type 2 diabetes has previously been weak 
and inconsistent.3 4 41 The potential overall benefits 
of fruits and vegetables have also been questioned 
within certain popular dietary regimens that favour 
low carbohydrate intake, including advice to limit 
the consumption of many fruits and vegetables.42 43 
Although five portions a day of fruit and vegetables 
have been recommended for decades, in 2014-15, 
69% of UK adults ate fewer than this number,44 and 
this proportion is even higher in European (EU) adults 
(86%).45 The low population level concordance with 
the “five a day” recommendation provides an incentive 
to quantify the benefits of making small changes in 
consumption of fruits and vegetables even below the 
threshold of the widely recommended guideline level, 
as suggested by our findings from the dose-response 
relationship of the biomarkers with fruit and vegetable 
intake presented in figure 3. Using biomarkers to 
quantify fruit and vegetable intake is an adjunct to 
self-reported questionnaires as objective assessment 
methods are less affected by the measurement errors 
of subjective dietary assessment tools. The use of 
biomarkers in this context is at present a research tool 
used to advance scientific understanding rather than a 
suggestion for their use in clinical practice.
This study also extends our understanding of the 
correlates of plasma vitamin C, total and individual 
carotenoids in different European countries. Previous 
studies,8 46 47 based on a subsample of about 3000 
people in the EPIC cohort, reported that the strongest 
predictors of individual carotenoids were fruits for β 
cryptoxanthin, total carrots and as in root vegetables 
for α carotene, and tomato products for lycopene. Our 
findings with a larger subcohort of people from the 
EPIC study are broadly consistent with the previous 
work, and provide additional information about the 
correlates of vitamin C, another strong biomarker 
of fruit and vegetable intake. In addition to the 
association of plasma vitamin C and carotenoids with 
fruit and vegetable intake, we have also described their 
association with other food groups, and demographic 
and lifestyle factors. We found a positive association 
between consumption of fruit and vegetable juice and 
the composite biomarker score, which could reflect a 
combination of factors, including naturally occurring 
vitamin C and the content of carotenoids in juice as well 
as fortified products. We could not distinguish between 
these, but our analyses of association between the 
biomarkers and incident type 2 diabetes were adjusted 
for vitamin supplement use, and suggest that as 
biomarkers of fruit and vegetable intake these findings 
endorse the consumption of fruit and vegetables, not 
that of supplements.
conclusions
Higher levels of plasma vitamin C, total and individual 
carotenoid biomarkers, and their composite biomarker 
score were associated with a lower incidence of type 
2 diabetes in diverse European populations in eight 
countries. These biomarkers are indicators of fruit and 
vegetable consumption, reducing the measurement error 
and bias of dietary self-reports. Our findings suggest 
that higher fruit and vegetable consumption is inversely 
associated with the incidence of type 2 diabetes, regard-
less of whether this increase in consumption is from a 
level below or above the recommended five a day thres-
hold. The public health implication of this observation 
is that the consumption of even a moderately increased 
amount of fruit and vegetables among populations who 
typically consume low levels could help to prevent type 
2 diabetes. It should be noted that these findings and 
other available evidence suggest that fruit and vegetable 
intake, rather than vitamin supplements, is potentially 
beneficial for the prevention of type 2 diabetes.
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